IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 325 filers reported holding IONIS PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.84 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,949,735 | +11.8% | 131,167 | +1.1% | 0.00% | +100.0% |
| Q2 2023 | $5,322,330 | -52.8% | 129,718 | -58.9% | 0.00% | -66.7% |
| Q1 2023 | $11,283,833 | -7.3% | 315,720 | -2.1% | 0.00% | -25.0% |
| Q4 2022 | $12,178,824 | -6.7% | 322,447 | +9.2% | 0.00% | 0.0% |
| Q3 2022 | $13,058,000 | +8.2% | 295,199 | -9.4% | 0.00% | 0.0% |
| Q2 2022 | $12,069,000 | +132.8% | 325,985 | +132.9% | 0.00% | +300.0% |
| Q1 2022 | $5,185,000 | +28.9% | 139,992 | +5.9% | 0.00% | 0.0% |
| Q4 2021 | $4,024,000 | -15.1% | 132,242 | -6.4% | 0.00% | 0.0% |
| Q3 2021 | $4,742,000 | -65.1% | 141,355 | -58.5% | 0.00% | -66.7% |
| Q2 2021 | $13,588,000 | -87.2% | 340,613 | -85.6% | 0.00% | -89.3% |
| Q1 2021 | $106,080,000 | -44.6% | 2,359,434 | -30.3% | 0.03% | -50.0% |
| Q4 2020 | $191,382,000 | +56.8% | 3,384,869 | +31.6% | 0.06% | +36.6% |
| Q3 2020 | $122,024,000 | -11.5% | 2,571,641 | +9.9% | 0.04% | -16.3% |
| Q2 2020 | $137,951,000 | +24.6% | 2,339,745 | -0.0% | 0.05% | +4.3% |
| Q1 2020 | $110,673,000 | -22.2% | 2,340,797 | -0.6% | 0.05% | +6.8% |
| Q4 2019 | $142,267,000 | -0.1% | 2,355,026 | -0.9% | 0.04% | +18.9% |
| Q3 2019 | $142,387,000 | -2.5% | 2,376,663 | +4.6% | 0.04% | -2.6% |
| Q2 2019 | $145,992,000 | +2160.6% | 2,271,539 | +2754.9% | 0.04% | +1800.0% |
| Q1 2019 | $6,458,000 | +139.0% | 79,565 | +59.2% | 0.00% | +100.0% |
| Q4 2018 | $2,702,000 | -78.7% | 49,982 | -79.7% | 0.00% | -75.0% |
| Q3 2018 | $12,698,000 | +50.1% | 246,190 | +21.3% | 0.00% | +33.3% |
| Q2 2018 | $8,460,000 | -5.3% | 203,018 | +0.2% | 0.00% | 0.0% |
| Q1 2018 | $8,932,000 | -19.8% | 202,633 | -8.5% | 0.00% | -25.0% |
| Q4 2017 | $11,142,000 | +67.2% | 221,506 | +68.5% | 0.00% | +100.0% |
| Q3 2017 | $6,664,000 | -59.9% | 131,445 | -59.8% | 0.00% | -60.0% |
| Q2 2017 | $16,618,000 | +85.3% | 326,676 | +46.4% | 0.01% | +66.7% |
| Q1 2017 | $8,970,000 | +2.8% | 223,137 | +22.3% | 0.00% | 0.0% |
| Q4 2016 | $8,729,000 | -6.0% | 182,499 | -28.0% | 0.00% | 0.0% |
| Q3 2016 | $9,290,000 | +14.6% | 253,548 | -27.1% | 0.00% | 0.0% |
| Q2 2016 | $8,104,000 | -69.4% | 347,935 | -46.9% | 0.00% | -72.7% |
| Q1 2016 | $26,523,000 | +190.0% | 654,875 | +343.4% | 0.01% | +175.0% |
| Q4 2015 | $9,146,000 | – | 147,690 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bellevue Group AG | 9,930,245 | $396,117,000 | 3.87% |
| Sicart Associates LLC | 368,409 | $14,696,000 | 3.50% |
| Camber Capital Management LP | 2,000,000 | $79,780,000 | 2.69% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 181,781 | $7,251,000 | 1.91% |
| SECTOR GAMMA AS | 263,488 | $10,511,000 | 1.86% |
| Parkman Healthcare Partners LLC | 136,380 | $5,440,000 | 1.19% |
| Eversept Partners, LP | 442,000 | $17,631,380 | 1.18% |
| Affinity Asset Advisors, LLC | 75,000 | $2,992,000 | 1.07% |
| TANAKA CAPITAL MANAGEMENT INC | 16,661 | $665,000 | 0.90% |
| Sonora Investment Management, LLC | 168,665 | $6,728,000 | 0.88% |